124.30
+1.80%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biogaia
Its shares trade on Nasdaq Stockholm under the ticker BIOG B.ST. It has been listed since 1 January 1998. In the fiscal year to 31 December 2025, it reported revenue of SEK 1.54bn and net income of SEK 332.8m. At that date it held total assets of SEK 1.60bn and shareholders' equity of SEK 1.31bn.
BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Jan 1998
- Employees
- 158
- Website
- biogaia.se ↗
Leadership
Pay as last reported
- Mr. Peter RothschildChairman of the Board, since 1996SEK 1.4m
- Ms. Theresa AgnewPresident, Chief Executive OfficerSEK 8.7m
- Mr. David DangoorIndependent Vice Chairman of the BoardSEK 622,000
- Mr. Alexander KotsinasChief Financial Officer, Executive Vice PresidentSEK 3.7m
- Mr. Ludvig MilessonChief Operating Officer
- Ms. Angelika KjelldorffChief Human Resources Officer
- Ms. Linda HagglundChief Marketing Officer
- Mr. Gianfranco GromponeChief Scientific Officer
- Mr. Sebastian HeimforsChief Commercial Officer
- Ms. Caroline MoforsChief Legal Officer
- Ms. Vanessa RothschildDirectorSEK 352,000
- Ms. Outi ArmstrongIndependent DirectorSEK 290,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 76
- Social
- 77
- Governance
- 73
- Direct emissions (scope 1)
- 77 t
- Energy emissions (scope 2)
- 205 t
- Value chain emissions (scope 3)
- 7,161 t
- Women in the workforce
- 57%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biogaia AB develops probiotic products based on Limosilactobacillus reuteri strains with documented health benefits.
- The company operates globally with a focus on paediatrics and adult health segments.
- Biogaia AB employs 158 full-time staff dedicated to probiotic product development and marketing.
Weaknesses
- Biogaia AB's business is limited to probiotic products without diversification into other health sectors.
- The company relies on a single bacterial strain for most of its product development.
- Biogaia AB has no presence in emerging markets like Asia or Africa.
Opportunities
- Biogaia AB can expand its adult health segment into new markets such as the United States.
- The growing global probiotics market offers opportunities for increased sales in Europe.
- Biogaia AB can leverage its Limosilactobacillus reuteri strain for new product development.
Threats
- Biogaia AB faces competition from established probiotic brands in the European market.
- Regulatory changes in the EU could impact probiotic product approvals.
- Biogaia AB's reliance on a single bacterial strain poses a risk if new strains emerge.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.